相关实验视频

Updated: May 3, 2026

Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles

Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles

Published on: January 4, 2012

纳米粒子处理细胞中的pioglitazone阶段和代谢作用通过快速可视化FLIM图像进行分析

Biagio Todaro¹, Luca Pesce¹, Francesco Cardarelli¹

¹NEST Laboratory, Scuola Normale Superiore, Piazza San Silvestro 12, 56127 Pisa, Italy.

Molecules (Basel, Switzerland)

|May 11, 2024

概括

我们开发了用于分相FLIM分析的新工具,可视化纳米颗粒中的药物pioglitazone (PGZ) 以及它对细胞代谢的影响. 这增强了对药物输送和潜在的抗糖尿病纳米疗法的理解.

科学领域:

先进的显微镜技术显微镜技术
生物医学工程生物医学工程
药理学药理学是指药理学的学科.

背景情况:

光终身成像显微镜 (FLIM) 分析材料和生物特性.
FLIM相位分析 (相位-FLIM) 提供了复杂光衰变的直观可视化.
皮奥格利塔 (PGZ) 治疗2型糖尿病;纳米粒子 (NP) 是药物输送的关键.

研究的目的:

介绍用于分相-FLIM分析的新型工具,增强分相位置和重量的可视化.
应用这些工具来分析含有药物的纳米粒子及其细胞效应.
提高对抗糖尿病纳米医学的药物封装和药理动学的理解.

主要方法:

开发并使用工具来编码分离器位置和重量在分离器图和图像中.
获取了用于分析的双光子FLIM数据.
应用于溶液/晶体中的皮奥格利塔 (PGZ) 方法,聚乳糖合糖酸 (PLGA) NP,以及INS-1 E细胞.

主要成果:

在溶液和晶体中成功可视化了PGZ的不同阶段.
确定了非标记PLGANP的相位图的位置.
评估了PGZ和PGZ载荷NP对INS-1E细胞的代谢作用.

结论:

开发的法索-FLIM工具为复杂的生物和材料科学数据提供了增强的可视化.
这种方法有助于更深入地了解药物-纳米粒子相互作用和细胞反应.
这项研究支持开发用于糖尿病治疗的先进神经学纳米工具.

关键词:

在 MATLAB 中,我们使用了 MATLAB 工具.在PLGA纳米粒子中.药物输送是药物输送的过程.光终身成像显微镜 (FLIM) 的应用胰岛素瘤 (INS-1) 细胞法索尔-FLIM分析皮奥格利塔的特征表征

更多相关视频

Using In Vitro Live-cell Imaging to Explore Chemotherapeutics Delivered by Lipid-based Nanoparticles

Using In Vitro Live-cell Imaging to Explore Chemotherapeutics Delivered by Lipid-based Nanoparticles

Published on: November 1, 2017

Author Spotlight: Standardizing Spheroid Formation Methods for Metabolic and Oxygenation Analysis Using Fluorescence Lifetime Imaging Microscopy

Author Spotlight: Standardizing Spheroid Formation Methods for Metabolic and Oxygenation Analysis Using Fluorescence Lifetime Imaging Microscopy

Published on: August 9, 2024

相关概念视频

Oral Hypoglycemic Agents: Biguanides and Glitazones

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...

Oral Hypoglycemic Agents: Glinides

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...